Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Prothena Corporation plc Ordinary Shares

PRTA

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Last trade $8.13
Day change +$0.155 (+1.94%)
Day range $7.70 – $8.20
Volume 289,259
Market cap $409M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$409.26M
Price / earnings
—
Price / book
1.52×
Price / sales
7.76×
EV / sales
2.61×
EV / EBITDA
-3.66×

Profitability

Earnings per share
-$0.47
Return on assets
-8.45%
Return on equity
-8.91%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
23.95×
Quick ratio
23.95×
Cash ratio
23.73×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$32.17M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PRTA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$620K$1.01M$51.08M$21K$2.42M$4.42M$2.83M$2.12M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$620K$1.01M$51.08M$21K$2.42M$4.42M$2.83M$2.12M
Selling, general and administrative$10.59M$10.9M$12.67M$12.65M$13.24M$15.91M$17.6M$16.85M
Research and development$8.43M$8.8M$12.63M$14.59M$28.94M$40.52M$50.81M$50.17M
Total operating expenses$19.44M$22.11M$21.05M$24.22M$42.66M$89.04M$68.41M$67.02M
Operating income-$18.82M-$21.1M$30.04M-$24.2M-$40.24M-$84.62M-$65.58M-$64.9M
Interest expense$0$0$0$2.65M$0$0$0$5.39M
Income before taxes-$16.51M-$18.58M$32.72M-$21.58M-$36.91M-$80.97M-$61.37M-$59.5M
Income taxes$2K$2K$1K$10K-$371K$44.8M-$1.18M-$1.55M
Net income-$16.51M-$18.58M$32.72M-$21.59M-$36.54M-$125.77M-$60.2M-$57.96M
Net income attributable to common shareholders-$16.51M-$18.58M$32.72M-$21.59M-$36.54M-$125.77M-$60.2M-$57.96M
EBITDA-$18.19M-$18.49M$25.98M-$26.99M-$39.53M-$51.78M-$65.36M-$64.68M
Basic earnings per share-$0.32-$0.36$0.61-$0.40-$0.68-$2.34-$1.12-$1.08
Diluted earnings per share-$0.32-$0.36$0.60-$0.40-$0.68-$2.34-$1.12-$1.10

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High?

Prothena (PRTA) has a mean analyst price target of $19.33, suggesting 120.2% upside potential from its current $8.78 price. The stock holds a Zacks Rank #2 (Buy) rating, supported by strong earnings estimate revisions that increased 58.8% over the past month. However, the article cautions that price targets alone should not drive investment decisions, as analysts often set overly optimistic targets due to business incentives.

Zacks Investment Research

Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates

Prothena (PRTA) reported a quarterly loss of $0.32 per share, beating consensus estimates of $0.38 loss, representing a 15.79% earnings surprise. However, the company missed revenue expectations significantly, posting $0.62 million versus the consensus estimate, down from $2.41 million year-over-year. The stock has underperformed the market by 24.5% year-to-date and carries a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Prothena's Partnership Strategy: Growth Driver or Limitation?

Prothena Corporation relies on partnerships with major pharmaceutical companies (Roche, Novo Nordisk, and Bristol Myers Squibb) to advance its neurodegenerative and rare disease treatments. The company received a $50M milestone payment for coramitug and estimates $3B in total future milestone payments plus royalties from partnered programs. While partnerships reduce financial burden and provide expertise, they also limit Prothena's control over key programs and expose the company to clinical and commercial risks.

Zacks Investment Research

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

In a comparison of two medical-biomedical stocks, CorMedix (CRMD) emerges as the superior value option over Prothena (PRTA). CRMD holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a forward P/E of 13.48 and PEG ratio of 1.35. PRTA, ranked #3 (Hold) with a Value grade of F, has a forward P/E of 66.51 and PEG ratio of 1.99, indicating it is significantly more expensive relative to its growth prospects.

GlobeNewswire Inc.

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.